Browse Studies — Arctuva

Phase 1

A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medicatio…

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

Estimated

~$10 – $7,500

Michael J. Dennis, MDNCT05774899

Phase 1

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

Estimated

~$10 – $8,750

Remix TherapeuticsNCT06118086

Observational

A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System

This pilot clinical trial studies transoral robotic surgery (TORS) in treating patients with benign or malignant tumors of the head and neck. TORS is a less in…

Recurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Squamous Cell Carcinoma of the Hypopharynx+48 more